EISAI CO

Eisai's investigational anti-MTBR tau antibody etalanetug (E2814) has been granted FDA Fast Track designation to expedite development for Alzheimer's disease treatment.

Eisai will present Phase Ib clinical study results exploring the efficacy of E2086, a selective orexin 2 receptor agonist, in patients with narcolepsy type 1 at World Sleep 2025.

Glenmark Pharmaceuticals Inc., USA announced the September 2025 launch of its generic Eribulin Mesylate Injection, marking the company's first complex generic product entry.

The FDA has approved a once-weekly autoinjector version of Eisai's Alzheimer's drug Leqembi, branded as Leqembi IQLIK, marking the first at-home dosing option for amyloid-based Alzheimer's therapy.

The FDA is requiring additional brain scans between the second and third Leqembi infusions after identifying six deaths early in treatment related to brain swelling complications.

Eli Lilly announced that Anne White, head of its neuroscience division, will retire in December after a 30-year career at the company.

The FDA has cleared SEED Therapeutics' IND application for ST-01156, a molecular glue degrader targeting RBM39, enabling a Phase 1 trial in advanced solid tumor and hematological malignancies.

Roche announced plans to test Trontinemab, an experimental drug designed to delay or prevent Alzheimer's disease symptoms in at-risk individuals.

Eisai Thailand has launched Beova® Tablets (vibegron), a selective β3-adrenergic receptor agonist for overactive bladder treatment, marking the first market entry in Eisai's licensed ASEAN region.

Biogen presents 48-month data from LEQEMBI's Clarity AD open-label extension study and introduces subcutaneous formulation for maintenance dosing at AAIC 2025.